Pharmaceutical Industry discussion, review, analysis, news and information.

Pharmos Corporation (Nasdaq: PARS)'s intravenous (i.v.) cannabinor passed phase 2a clinical trial in post-operative pain in over 100 male patients undergoing third molar dental extraction.

12 mg cannabinor – the lowest dose used in the single-center, randomized, double-blinded, placebo-controlled, single administration of different cannabinor doses study – produced a statistically significant decrease in pain as compared to placebo.

According to Arnon Aharon, M.D., Senior Director of Clinical Development:

"We are encouraged by the analgesic signal of cannabinor in the nociceptive pain study, but the pattern of the results is not that easily interpreted.

Taken together with the results from the Phase 2a experimentally induced pain study, the data do suggest that cannabinor has analgesic properties in acute pain models and the potential to be active in the targeted indications of neuropathic pain and chronic nociceptive pain where the drug would be given chronically."